Merck MRK and its Japanese partner Daiichi Sankyo announced that the FDA has accepted the biologics license application (BLA) seeking approval for ifinatamab deruxtecan (I-DXd), a B7-H3-directed DXd ...
Lung cancer driven by mutated HER2 proteins already has a targeted therapy, the blockbuster product Enhertu from AstraZeneca and Daiichi Sankyo. A Boehringer Ingelheim drug has won FDA approval for ...
Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult ...
When lung cancer advances after initial lines of therapy, the treatment options dwindle. An AbbVie drug gives patients a new choice as the first FDA-approved treatment for advanced cases of non-small ...
Partners Daiichi Sankyo and Merck & Co. are sharing new phase 2 data for their investigational antibody-drug conjugate, findings the pair think will help score accelerated approval in pretreated small ...
After flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, AbbVie is advancing its solid tumor ambitions with a new FDA green light.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results